Be-cause Health & QUAMED literature updates

Ref. Tuck C et al.  Quality assurance and cancer medicines in low-income and middle-income countries. Lancet Oncol 2021; 22: 301-3. Available at

Dear Friend,

I would like to highlight a short but important commentary from Tuck and colleagues, raising awareness on the quality challenges for cancer medicines available in low- and middle-income countries (see Substandard and falsified medicines may only further add to the existing global inequalities in access to cancer treatment, and they should be detected and prevented by strong(er) regulatory systems. Furthermore, as noted by the authors, ‘’ ensuring patients can access and afford medicines through formal, quality-assured routes are key’’. This ‘’requires sufficient coverage for cancer medicines in national insurance schemes and initiatives that provide community access to these medicines. The expense of cancer medicines often prevents their inclusion in national insurance schemes, despite being listed on the WHO Essential Medicines List’’ (and I would add that this further confirms the need for more transparency on cost-setting mechanisms for medicines).

I would also like to drive your attention to the new VACCINE report from our IDDO friends, that can be downloaded from the following link:

It is worrying that unauthorized copies of approved COVID-19 vaccines have been reported for Pfizer/BioNTech, AstraZeneca, Sinovac, Sinopharm, and Moderna. As noted by the authors, ‘’we urgently need joined-up interventions to reduce the risk of SF COVID-19 vaccines on global public health, through significant enhancement in global capacity for their prevention, detection, and response’’. And, obviously, the ‘’market opportunity’’ for criminal group would be decreased or eliminated by global access to the vaccines.

Have a nice reading,


PS Are you on Twitter? Follow us for more updates at @RRavinetto and @QUAMED1

This may interest you